Intracranial metastases from adenocarcinoma of cervix: A case report

Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Center, Rohini-V, New Delhi, India.
International Journal of Gynecological Cancer (Impact Factor: 1.96). 05/2005; 15(3):561-3. DOI: 10.1111/j.1525-1438.2005.15326.x
Source: PubMed


Nagar YS, Shah N, Rawat S, Kataria T. Intracranial metastases from adenocarcinoma of cervix: a case report. Int J Gynecol Cancer 2005;15:561–563. Carcinoma of cervix usually spreads contiguously to the adjacent organs, by lymphatics to the pelvic and para-aortic lymph nodes and by hematogenous route to distant organs. The common sites of distant metastasis are lung, supraclavicular lymph nodes, liver, and bones. The brain is a rare site of metastasis. We report here a rare case of a 72-year-old woman with carcinoma of cervix, FIGO stage IIA, who developed metastases to the brain.


Available from: Sheh Rawat, May 14, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents an approach to determine the energy absorption capacity of metal oxide surge arrester resistors. The proposed approach deals with the discharge current peak versus discharge current time relation. A testing method and a statistical evaluation are proposed. After determining the discharge current withstand limit of the tested metal oxide resistors, the prospective energy absorption capacity limit is computed. Finally, comments on the obtained results are presented
    Electrical Insulation, 1996., Conference Record of the 1996 IEEE International Symposium on; 07/1996
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to describe the features of patients with brain metastasis from cervical cancer. Twelve patients with brain metastasis from cervical cancer were identified. Information regarding symptoms, treatment, and survival was analyzed. The incidence of brain metastasis in our population was 0.77%. Median patient age at initial diagnosis of cervical cancer was 43.5 years (range 29-57 years) compared with 44.5 years (range 31-58 years) at identification of brain metastasis. Six patients had FIGO stage IB disease; three had stage IIB disease; and one each had stage IIIA, IIIB, and IVB disease. The median interval from diagnosis of cervical cancer to identification of brain metastasis was 17.5 months (range 1.1-96.1 months). All but one patient presented with neurologic symptoms. Eight patients received whole-brain irradiation and steroids, three received steroids alone, and one underwent surgery, followed by irradiation. All the patients who received whole-brain irradiation experienced improvement in their symptoms. Median survival from diagnosis of brain metastasis to death was 2.3 months (range 0.3-7.9 months). Five patients who received chemotherapy after brain irradiation had a median survival of 4.4 months compared to 0.9 months for those who received no additional treatment after brain irradiation (P= .016). Most patients with brain metastasis from cervical cancer presented with neurologic sequelae. Brain irradiation improved these symptoms. Survival after diagnosis of brain metastasis was poor; however, patients who received chemotherapy after brain irradiation appeared to have improved survival.
    International Journal of Gynecological Cancer 01/2007; 17(1):141-6. DOI:10.1111/j.1525-1438.2007.00808.x · 1.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Greater than one-half of all intracranial tumors in adults represent metastases from disseminated systemic malignancies. Abundant class I evidence has been accumulated for the past two decades that demonstrates improved survival and quality of life with surgical resection or SRS for appropriate patients. In some tumor types, WBRT can effectively treat, prevent and/or delay recurrences and improve survival as well. However, several factors may preclude either surgery or radiation therapy (e.g., number of metastases, co-existing medical or neurological conditions) and in such patients the mainstay of treatment is chemotherapy or other biologic targeted therapy.
    Cancer treatment and research 02/2007; 136:185-97. DOI:10.1007/978-0-387-69222-7_10
Show more